Close Menu

The New York Times profiles GlaxoSmithKline's Andrew Witty, particularly focusing on his efforts to help the poor. Witty has promised to limit the price of GSK drugs in poor countries to no more than 25 percent of what they charge in wealthy nations and to donate one-fifth of the profits from poor countries to build up their healthcare systems. Witty, of course, has his detractors.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.